-
First secondary progressive multiple sclerosis (SPMS) oral drug! Novarma Mayzent improves cognition
Time of Update: 2020-09-26
Over time, up to 50-60% of RRMS patients will develop into SPMS, and Mayzent ® is a next-generation, selective 1-phosphate pyrethroid (S1P) regulator, the world's first approved oral disease correction therapy (DMT) drug for SPMS, and early on on treatment can effectively slow progression and cognitive decline in disability.
-
Great praise! Five new Novartis drugs were approved in Japan on the same day: Tabrecta, Entresto, Mayzent, Enerzair and Atectura.
Time of Update: 2020-07-19
, 2020 /PRNewswire/ -- Novartis has announced that Japan's Ministry of Health, Labour (MHLW) has approved five drugs simultaneously: - Tabrecta (capinmatib, caprectib, Originally known as INC28
-
FDA approves Novartis Mayzent (siponimod) for treatment of adult patients with recurrent multiple sclerosis
Time of Update: 2020-06-10
recently, Novartis (http:// announced that the U.S FDA (http:// approved its development of Mayzent (http:// for the treatment of recurrent multiple sclerosis (RMS) adult patients, including a
-
The first oral medication for secondary progressive multiple sclerosis (SPMS)! Mayzent, a new
Time of Update: 2020-01-22
January 22, 2020 / BIOON / -- Novartis, a Swiss pharmaceutical giant Novartis recently announced that the European Commission (EC) has approved mayzent (siponimod) for the treatment of adult patients
-
Second progressive multiple sclerosis (SPMS) is the first oral drug! Mayzent, a new generation
Time of Update: 2019-11-18
November 18, 2019 / BIOON / - Novartis, a Swiss pharmaceutical giant Novartis recently announced that the European Drug Administration (EMA) Committee on human medicinal products (CHMP) has issued a p